The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study

“…14 Similarly to previous studies, our study confirms a higher risk of pneumococcal disease, higher incidence of hospitalization, and higher case fatality rate in those with underlying clinical conditions for whom pneumococcal vaccination is already recommended. 13 The effect of being in a risk group was less marked in those aged 65 y and over.…”

“…invasive pneumococcal disease among patients with risk factors for pneumococcal disease 13 and with those from the US, where the rate of all-cause pneumonia, pneumococcal pneumonia and invasive pneumococcal disease substantially increased with the accumulation of concurrent at-risk conditions among persons 18-49 y. 14 Similarly to previous studies, our study confirms a higher risk of pneumococcal disease, higher incidence of hospitalization, and higher case fatality rate in those with underlying clinical conditions for whom pneumococcal vaccination is already recommended.…”

“…It is unclear whether conjugate vaccines may offer an immunological advantage in these groups. 13 Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) has shown to be effective in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic communityacquired pneumonia and vaccine type invasive pneumococcal disease in adults 65 y of age or older. 18 The Spanish Association of Preventive Medicine, Public Health and Hygiene recommends a dose of PCV13 followed at 6-12 months by a dose of PPSV23 in all adults aged 65 years who have not previously received pneumococcal vaccine and a dose of PCV13 at least 12 months after the PPSV23 in those who have previously received pneumococcal vaccine.…”

“…pneumococcal infections associated with certain chronic medical conditions have persisted. 20,21 Meanwhile some studies show that the indirect protection from conjugate generalized vaccination of children may benefit high-risk groups once herd immunity takes effect, 13 other studies show that despite widespread use of pneumococcal conjugate vaccines, rates of pneumonia and invasive pneumococcal disease remain disproportionately high in adults with at-risk conditions, including those with conditions not currently included in the Advisory Committee on Immunization Practices guidelines for prevention and those with multiple at-risk conditions. 14 Although the herd effects of the infant vaccination program using the 13 valent pneumococcal conjugate vaccine (PCV13) will in time indirectly protect people at high risk, suggesting then that PCV vaccination of high-risk groups may not provide substantial additional benefit, the burden of preventable pneumococcal disease will remain high during the first years after the introduction of the infant vaccination program.…”

Hastalarımız pnömokok așısını biliyor mu?

“…Üçüncü basamak sağlık merkezlerinde yapılan araştırmalarda ise pnömokok enfeksiyonlarına karşı aşılanma oranlarının %10-15 arasında değiştiği gösterilmiştir (11,12 (17). Ayrıca diyabeti olan hastalarda toplum kökenli pnömoni riski 1,4 kat, invaziv pnömokokal hastalık riski ise 1,4-4,6 kat artmıştır (18)(19)(20). Yaş ilerledikçe sağlık merkezlerine kümülatif başvuru sayısının artmasına bağlı olarak sağlık personelinin aşı hakkında tekrar tekrar bilgilendirmesi, aşıyı önermesi ve reçetelendirmesi yaş ile aşılanma oranında artışın diğer bir sebebi olabilir.…”